Retatrutide is not approved yet. Here's when is retatrutide expected to be available, plus the phase 3 timeline and what could delay the launch.
Retatrutide is not available yet. Eli Lilly's investigational triple-agonist is still working through phase 3 clinical trials, and no regulatory agency has approved it for sale, so it cannot legally be prescribed or purchased in the United States. Based on current trial schedules and Lilly's own public guidance, the most credible estimates put a US approval somewhere between late 2026 and 2027, with pharmacy availability following a few months after that.
That range is wide because it has to be. Nobody, including the manufacturer, can promise a date before the FDA completes its review. What follows is the clearest picture available today: the milestones still ahead, the risks that could push things back, and what you can do in the meantime.
What Retatrutide Is and Why It Isn't on the Market
Retatrutide is a once-weekly injection that activates three hormone receptors at the same time: GLP-1, GIP, and glucagon. That triple mechanism is what separates it from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP).
In a phase 2 trial published in the New England Journal of Medicine in 2023, participants with obesity lost an average of roughly 24% of their body weight after 48 weeks on the highest dose. Those results are why interest is so intense, and also why the drug still faces years of testing.
Retatrutide is not FDA-approved for human use in the United States. Strong phase 2 data does not make a drug available. Approval requires large phase 3 trials that confirm the benefits, capture rare side effects, and prove that manufacturing is consistent batch to batch.
Where the Phase 3 Program Stands
Lilly is running retatrutide through two late-stage programs: TRIUMPH, which focuses on obesity and related conditions, and TRANSCEND, which focuses on type 2 diabetes.
| Program | Population Studied | Primary Focus |
|---|---|---|
| TRIUMPH-1 | Adults with obesity, without diabetes | Weight loss and safety |
| TRIUMPH-2 | Adults with obesity and type 2 diabetes | Weight loss with diabetes |
| TRIUMPH-3 | Adults with obesity and cardiovascular disease | Weight loss plus heart outcomes |
| TRIUMPH-4 | Adults with obesity and knee osteoarthritis | Weight loss plus joint pain |
| TRANSCEND-T2D | Adults with type 2 diabetes | Blood sugar control |
Each study has to finish, lock its database, and report topline results before Lilly can assemble a regulatory submission. Several of those readouts have been landing in 2025 and 2026, which is why the short answer to when will retatrutide be available now hinges on how quickly those results convert into a filing.
Typical Timeline From Phase 3 to Pharmacy Shelves
| Milestone | What Happens | Best Current Estimate |
|---|---|---|
| Phase 3 topline results | Trials report weight loss and safety data | 2025–2026 |
| Regulatory submission | Lilly files a New Drug Application with the FDA | Possibly 2026 |
| FDA review | Standard review runs about 10–12 months; priority review about 6 | 6–12 months after filing |
| Approval and launch | Prescriptions can be written and supply ramps up | Late 2026 to 2027 in most forecasts |
What Could Delay the Retatrutide Launch
- Safety findings. A signal in any large trial can trigger extra analyses or an FDA advisory committee meeting, adding months.
- A complete response letter. The FDA can decline to approve and request more data, which often adds a year or more.
- Manufacturing scale-up. Peptide injectables are difficult to produce at volume, and Lilly is already supplying a crowded market.
- Competition and pricing pressure. Newer injectables and oral options can change both the review questions and the commercial strategy.
Because of these variables, any precise retatrutide launch date you see on social media is a guess, not news.
Can You Buy Retatrutide Right Now?
No legitimate pharmacy sells retatrutide, and no telehealth service can legally prescribe it. Anything marketed online as "retatrutide" is either a different drug, a mislabeled product, or an unregulated research chemical that has never been tested in people.
That gray market is worth understanding before you spend money on it. The same vendors that sell AOD-9604 — the peptide behind searches like when to take aod 9604 — now advertise retatrutide vials. Buyers in that space often ask does kpv need to be refrigerated or does bac water need to be refrigerated, and the honest answer for retatrutide is that nobody has established storage, purity, or dosing standards for a product that isn't legally sold.
Unapproved peptide powders sold online are not guaranteed to contain the labeled ingredient, and self-dosing with them has caused serious harm in reported cases. Talk with a licensed healthcare professional before using any injectable peptide.
What to Do While You Wait
Several GLP-1 and dual-agonist medications are already approved and available, including semaglutide (Wegovy) and tirzepatide (Zepbound). A clinician can help you weigh what's on the market today against what's still in development.
Clinical trials are another realistic path. Retatrutide studies are listed on ClinicalTrials.gov, and participants receive the drug or a placebo with regular medical monitoring at no cost.
If injections are the sticking point, the same curiosity drives searches like when will eli lilly weight loss pill be available — that refers to orforglipron, an oral GLP-1 pill that could reach the market around the same era as retatrutide.
How to Follow the Timeline Yourself
- Check ClinicalTrials.gov for retatrutide study status updates.
- Read Lilly's quarterly earnings releases, where filing timelines are frequently discussed.
- Watch FDA announcements for accepted applications, review designations, and advisory committee meetings.
- Ignore firm launch dates from anyone who is not the manufacturer or the FDA.
For now, the safest conclusion is simple. Retatrutide remains an investigational drug, its approval window sits in the 2026–2027 range under current expectations, and no one should buy it from an unregulated seller in the meantime.
Frequently Asked Questions
Is retatrutide FDA approved?
No. Retatrutide is an investigational drug, and Eli Lilly is still conducting phase 3 trials. The FDA has not accepted a New Drug Application for retatrutide, so it cannot be prescribed, sold, or legally imported for personal use in the United States.
Will retatrutide be available in 2026?
It's possible but not guaranteed. If Lilly files a New Drug Application in 2026 and the FDA grants a priority review, an approval could land that same year. Most industry forecasts point to late 2026 at the earliest, with 2027 a more realistic window for broad pharmacy availability.
Can I get retatrutide through a clinical trial?
Yes, in some cases. Retatrutide phase 3 trials are listed on ClinicalTrials.gov, and eligibility depends on factors like weight, health history, and location. Participants receive the drug or a placebo plus monitoring at no cost, but they are not told which one they are receiving.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.